CNBX Pharmaceuticals Inc. (CNBX): Cash & Equivalents
$15.1K
As of 2025-08-31
$9.5K
As of 2026-05-31
-49.5%
3-year compound annual growth
-54.5%
5-year compound annual growth
-5.0%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $15.1K | -42.8% | 2025-12-01, Balance as of period end |
| 2024-08-31 | $26.4K | -79.6% | 2025-12-01, Balance as of period end |
| 2023-08-31 | $129.7K | +10.4% | 2024-11-29, Balance as of period end |
| 2022-08-31 | $117.5K | -91.5% | 2023-11-30, Balance as of period end |
| 2021-08-31 | $1.39M | +78.3% | 2022-11-30, Balance as of period end |
| 2020-08-31 | $777.6K | +192.4% | 2021-11-29, Balance as of period end |
| 2019-08-31 | $266.0K | -80.9% | 2020-11-04, Balance as of period end |
| 2018-08-31 | $1.39M | -58.6% | 2019-11-29, Balance as of period end |
| 2017-08-31 | $3.37M | n/m | 2018-11-29, Balance as of period end |
| 2016-08-31 | $19.1K | -24.2% | 2017-12-08, Balance as of period end |
| 2015-08-31 | $25.2K | -74.5% | 2017-12-08, Balance as of period end |
| 2014-08-31 | $98.8K | +35.8% | 2016-01-07, Balance as of period end |
| 2013-08-31 | $72.8K | n/a | 2015-10-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| CNBX Pharmaceuticals Inc. (CNBX) | 2025-08-31 | $15.1K | -42.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare CNBX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗